1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Protein Homeostasis
3.3. Post Translational Protein Modifications 3.4. Ubiquitin and the Ubiquitin Proteasome System (UPS) 3.4.1. Structure and Functions of Ubiquitin
3.4.2. Overview of the UPS
3.4.2.1. Components of the UPS
3.4.2.2. Ubiquitin-based Protein Degradation Pathway
3.5. Therapeutic Applications of the UPS
3.6. Ubiquitin Enzyme Inhibitors
3.6.1. Advantages and Challenges
3.7. Overview of Targeted Protein Degradation
3.7.1. Historical Development of Protein Degraders
3.7.2. Types of Protein Degraders
3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)
3.7.2.2. Other Chimeric Protein Targeting Molecules
3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)
3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)
3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)
3.7.2.3. Epichaperome Inhibitors
3.7.2.4. Hydrophobic Tags
3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)
3.7.2.6. Molecular Glues
3.7.2.7. Protein Homeostatic Modulators
3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)
3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)
3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors
3.8. Growth Drivers and Roadblocks
3.9. Recent Developments and Upcoming Trends
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Type of Target Protein
4.2.6. Analysis by Type of Target Enzyme
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms
4.4. Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Size of Company
4.4.3. Analysis by Type of Protein Degrader
4.4.4. Analysis by Location of Headquarters
4.4.5. Leading Developers: Analysis by Number of Drug Candidates
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Late-stage Clinical Candidates
5.2.1. Radius Health
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Targeted Protein Degradation-based Drug Portfolio
5.2.1.3.1. Elacestrant (RAD1901)
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Celgene
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Targeted Protein Degradation-based Drug Portfolio
5.2.2.3.1. Avadomide (CC-122)
5.2.2.3.2. Iberdomide (CC-220)
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Sanofi Genzyme
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Targeted Protein Degradation-based Drug Portfolio
5.2.3.3.1. SAR439859
5.2.3.4. Recent Developments and Future Outlook
5.3. Developers with Preclinical / Early-stage Clinical Candidates
5.3.1. Arvinas
5.3.2. Captor Therapeutics
5.3.3. Genentech
5.3.4. Kymera Therapeutics
5.3.5. Mission Therapeutics
5.3.6. Progenra
5.3.7. Zenopharm
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number of Clinical Trials
6.3.3. Geographical Analysis by Enrolled Patient Population
6.3.4. Analysis by Type of Protein Degrader
6.3.5. Analysis by Phase of Development
6.3.6. Analysis by Study Design
6.3.7. Analysis by Type of Sponsor / Collaborator
6.3.8. Most Active Players: Analysis by Number of Registered Trials
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Therapeutic Area
6.3.11. Analysis by Clinical Endpoints
7. KOL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators Involved in Clinical Trials
7.3.1. Analysis by Designation
7.3.2. Analysis by Phase of Development and Type of Protein Degrader
7.3.3. Analysis by Focus Therapeutic Area
7.3.4. Analysis by Type of Organization
7.3.5. Analysis by Location of Organization
7.3.6. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
7.6. Profiles of Most Active KOLs
7.6.1. Profile: KOL A (Barbara Ann Karmanos Cancer Center)
7.6.2. Profile: KOL B (Celgene)
7.6.3. Profile: KOL C (Feinberg School of Medicine, Northwestern University)
7.6.4. Profile: KOL D (Royal Marsden NHS Foundation Trust)
7.6.5. Profile: KOL E (Samus Therapeutics)
7.6.6. Profile: KOL F (Stanford Women Cancer Center)
7.6.7. Profile: KOL G (University of North Carolina at Chapel Hill)
7.6.8. Profile: KOL H (University of Toledo)
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Collaborations and Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Protein Degrader
8.3.4. Analysis by Technology Platform
8.3.5. Analysis by Therapeutic Area
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Geographical Analysis
8.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
8.3.7.2. Intercontinental and Intracontinental Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Types of Degraders
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.6. Analysis by Amount Invested across Different Technology Platforms
9.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
9.3.8. Most Active Investors: Analysis by Participation
9.3.9. Geographical Analysis by Amount Invested
9.4. Concluding Remarks
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
10.4. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030
10.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
10.4.1.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030
10.4.1.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, 2020-2030
10.4.1.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030
10.4.1.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, 2020-2030
10.4.1.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, 2020-2030
10.4.1.6. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030
10.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
10.4.2.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, 2020-2030
10.4.2.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2020-2030
10.4.2.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030
10.4.2.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, 2020-2030
10.4.2.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030
10.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
10.4.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030
10.4.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030
10.4.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030
10.4.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
10.4.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030
10.4.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030
10.4.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030
10.4.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2020-2030
11. EXECUTIVE INSIGHTS
12. CONCLUDING REMARKS
12.1. Chapter Overview
12.2. Key Takeaways
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List of Figures
Figure 3.1 Important Mechanisms of Protein Surveillance
Figure 3.2 Common Types of Post-translational Modifications
Figure 3.3 Mechanism-based Analogies in Phosphorylation and Ubiquitination
Figure 3.4 Key Differences in Phosphorylation and Ubiquitination
Figure 3.5 Types of Proteins Associated with Ubiquitin
Figure 3.6 Genetic Evolution of the UPS in Eukaryotes
Figure 3.6 Key Components of the UPS
Figure 3.7 Key Steps Involved in Protein Degradation via the Ubiquitin-Proteasome Pathway
Figure 3.8 Different Modes of Ubiquitination
Figure 3.9 Biological Functions of Ubiquitination
Figure 3.10 Disease Development Process in the UPS
Figure 3.11 Key Therapeutic Areas Targeted by UPS Modulating Drug Candidates
Figure 3.12 Key Differences Between Protein Degrader and Protein Inhibitor
Figure 3.13 Historical Evolution of Targeted Protein Degradation
Figure 3.14 Types of Protein Degraders
Figure 3.15 Mechanism of Action of PROTACs
Figure 3.16 Mechanism of Action of ENDTACs
Figure 3.17 Mechanism of Action of LYTACs
Figure 3.18 Mechanism of Action of PHOTACs
Figure 3.19 Mechanism of Action of Epichaperome Inhibitors
Figure 3.20 Mechanism of Action of Hydrophobic Tags
Figure 3.21 Mechanism of Action of IMiDs
Figure 3.22 Mechanism of Action of Molecular Glues
Figure 3.23 Mechanism of Action of Protein Homeostatic Modulators
Figure 3.24 Mechanism of Action of SHRDs
Figure 3.25 Mechanism of Action of SNIPERs
Figure 3.26 Key Growth Drivers and Roadblocks Related to Targeted Protein Degraders
Figure 4.1 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Protein Degrader
Figure 4.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development
Figure 4.3 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development and Type of Protein Degrader
Figure 4.4 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area
Figure 4.5 Popular Indications: Distribution by Number of Drug Candidates
Figure 4.6 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Type of Protein Degrader
Figure 4.7 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Figure 4.8 Popular Target Enzymes: Distribution by Number of Drug Candidates
Figure 4.9 Popular Target Proteins: Distribution by Number of Drug Candidates
Figure 4.10 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Type of Protein Degrader
Figure 4.11 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Phase of Development
Figure 4.12 Targeted Protein Degradation-based Therapeutics and Technologies: Grid Analysis
Figure 4.13 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Therapy
Figure 4.14 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Route of Administration
Figure 4.15 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Year of Establishment
Figure 4.16 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Location of Headquarters
Figure 4.17 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Size of Company
Figure 4.18 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Type of Protein Degrader
Figure 4.19 Targeted Protein Degradation-based Therapeutics and Technologies: Geographical Distribution of Industry Players by Type of Protein Degrader
Figure 4.20 Leading Developers: Distribution by Number of Drug Candidates
Figure 5.1 Radius Health: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 5.2 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 5.3 Sanofi Genzyme: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 6.1. Clinical Trials: Distribution by Trial Status
Figure 6.2 Clinical Trials: Cumulative Distribution by Registration Year, Pre-2012-Q3 2019
Figure 6.3 Clinical Trials: Geographical Distribution of Trials
Figure 6.4 Clinical Trials: Geographical Distribution of Enrolled Patient Population
Figure 6.5 Clinical Trials: Distribution by Trial Phase
Figure 6.6 Clinical Trials: Distribution by Type of Protein Degrader
Figure 6.7 Clinical Trials: Distribution by Type of Protein Degrader and Trial Phase
Figure 6.8 Clinical Trials: Distribution by Therapeutic Area
Figure 6.9 Popular Indications: Distribution by Number of Trials
Figure 6.10 Clinical Trials: Distribution by Popular Indications and Phase of Development
Figure 6.11 Clinical Trials: Distribution by Therapeutic Area, Type of Protein Degrader, Trial Phase and Trial Registration Year
Figure 6.12 Clinical Trials: Distribution by Study Design
Figure 6.13 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 6.14 Most Active Players: Distribution by Number of Registered Trials
Figure 6.15 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Figure 6.16 Clinical Trials: Popular Keywords
Figure 6.17 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Figure 7.1 KOLs: Geographical Distribution of Principal Investigators
Figure 7.2 KOLs: Distribution by Designation
Figure 7.3 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Figure 7.4 KOLs: Distribution by Therapeutic Area
Figure 7.5 KOLs: Distribution by Type of Organization
Figure 7.6 KOLs: Distribution by Location of Organization
Figure 7.7 Leading Organizations: Distribution by Number of Principal Investigators
Figure 7.8 KOLs: Dot-Plot of Principal Investigators
Figure 7.9 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 7.10 Most Prominent KOLs
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Figure 8.5 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Partnership Model
Figure 8.7 Leading Technology Platforms: Distribution by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.9 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Figure 8.10 Most Active Players: Distribution by Number of Partnerships
Figure 8.11 Most Active Players: Regional Distribution by Number of Partnerships
Figure 8.12 Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Figure 9.1 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Figure 9.2 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Figure 9.3 Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 9.4 Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Figure 9.5 Funding and Investments: Distribution by Type of Funding
Figure 9.6 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 9.7 Funding and Investments: Summary of Investments, 2014-Q3 2019 (USD Million)
Figure 9.8 Popular Protein Degraders: Distribution by Number of Funding Instances
Figure 9.9 Popular Protein Degraders: Distribution by Amount Invested (USD Million)
Figure 9.10 Funding and Investments: Year-wise Trend of Amount Invested across Different Degraders, 2014-Q3 2019 (USD Million)
Figure 9.11 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Figure 9.12 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Figure 9.13 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Degraders
Figure 9.14 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Figure 9.15 Most Active Players: Distribution by Number of Instances
Figure 9.16 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 9.17 Most Active Investors: Distribution by Number of Instances
Figure 9.18 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 9.19 Funding and Investment Summary
Figure 10.1 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
Figure 10.2 Targeted Protein Degradation-based Therapeutics and Technologies: Average Value and Volume of Upfront Payments (Units, USD Million)
Figure 10.3 Targeted Protein Degradation-based Therapeutics and Technologies: Average Value and Volume of Milestone Payments (Units, USD Million)
Figure 10.4 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030 (USD Million)
Figure 10.5 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, 2020-2030 (USD Million)
Figure 10.6 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030 (USD Million)
Figure 10.7 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, 2020-2030 (USD Million)
Figure 10.8 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030 (USD Million)
Figure 10.9 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, 2020-2030 (USD Million)
Figure 10.10 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, 2020-2030 (USD Million)
Figure 10.11 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030 (USD Million)
Figure 10.12 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 10.13 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, 2020-2030 (USD Million)
Figure 10.14 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 10.15 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 10.16 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, 2020-2030 (USD Million)
Figure 10.17 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030 (USD Million)
Figure 10.18 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 10.19 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030 (USD Million)
Figure 10.20 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030 (USD Million)
Figure 10.21 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030 (USD Million)
Figure 10.22 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, 2020-2030 (USD Million)
Figure 10.23 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030 (USD Million)
Figure 10.24 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030 (USD Million)
Figure 10.25 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 10.26 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, 2020-2030 (USD Million)
List of Tables
Table 3.1 Structural Classification of Ubiquitin
Table 4.1 Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
Table 4.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Table 4.3 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Target Enzyme, Target Protein, Signaling Pathway, Type of Therapy and Route of Administration
Table 4.4 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Marketed First Generation Protein Degraders
Table 4.5 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Research Tools / Key Technology Platforms
Table 4.6 Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
Table 5.1 Radius Health: Key Highlights
Table 5.2 Drug Profile: Elacestrant (RAD1901)
Table 5.3 Radius Health: Recent Developments and Future Outlook
Table 5.4 Celgene: Key Highlights
Table 5.5 Drug Profile: Avadomide (CC-122)
Table 5.6 Drug Profile: Iberdomide (CC-220)
Table 5.7 Celgene: Recent Developments and Future Outlook
Table 5.8 Sanofi Genzyme: Key Highlights
Table 5.9 Drug profile: SAR439859
Table 5.10 Sanofi Genzyme: Recent Developments and Future Outlook
Table 5.11 Arvinas: Key Highlights
Table 5.12 Captor Therapeutics: Key Highlights
Table 5.13 Genentech: Key Highlights
Table 5.14 Kymera Therapeutics: Key Highlights
Table 5.15 Mission Therapeutics: Key Highlights
Table 5.16 Progenra: Key Highlights
Table 5.17 Zenopharm: Key Highlights
Table 6.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
Table 6.2 Clinical Trials: Distribution by Registration Year and Type of Protein Degrader
Table 6.3 Clinical Trials: Popular Clinical Endpoints by Phase of Development
Table 7.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
Table 7.2 KOLs: Roots Analysis Proprietary Scoring System
Table 7.3 Profile: KOL A (Barbara Ann Karmanos Cancer Center)
Table 7.4 Profile: KOL B (Celgene)
Table 7.5 Profile: KOL C (Feinberg School of Medicine, Northwestern University)
Table 7.6 Profile: KOL D (Royal Marsden NHS Foundation Trust)
Table 7.7 Profile: KOL E (Samus Therapeutics)
Table 7.8 Profile: KOL F (Stanford Women Cancer Center)
Table 7.9 Profile: KOL G (University of North Carolina at Chapel Hill)
Table 7.10 Profile: KOL H (University of Toledo)
Table 8.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Partnerships, 2014-Q3 2019
Table 8.2 Most Active Players: Regional Distribution by Number of Partnerships
Table 9.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Funding Instances, 2014-Q3 2019
Table 9.2 Targeted Protein Degradation-based Therapeutics and Technologies: Summary of Investments
Table 11.1 Xios Therapeutics: Key Highlights
Table 12.1 Targeted Protein Degradation-based Therapeutics and Technologies: Key Takeaways of the Report
Table 13.1 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Protein Degrader
Table 13.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development
Table 13.3 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development and Type of Protein Degrader
Table 13.4 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area
Table 13.5 Popular Indications: Distribution by Number of Drug Candidates
Table 13.6 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Type of Protein Degrader
Table 13.7 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Table 13.8 Popular Target Enzymes: Distribution by Number of Drug Candidates
Table 13.9 Popular Target Proteins: Distribution by Number of Drug Candidates
Table 13.10 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Type of Protein Degrader
Table 13.11 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Phase of Development
Table 13.12 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Therapy
Table 13.13 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Route of Administration
Table 13.14 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Year of Establishment
Table 13.15 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Location of Headquarters
Table 13.16 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Size of Company
Table 13.17 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Type of Protein Degrader
Table 13.18 Targeted Protein Degradation-based Therapeutics and Technologies: Geographical Distribution of Industry Players by Type of Protein Degrader
Table 13.19 Leading Developers: Distribution by Number of Drug Candidates
Table 13.21 Radius Health: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.22 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.23 Sanofi Genzyme: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.24 Clinical Trials: Distribution by Trial Status
Table 13.25 Clinical Trials: Cumulative Distribution by Registration Year, Pre-2012-Q3 2019
Table 13.26 Clinical Trials: Geographical Distribution of Trials
Table 13.27 Clinical Trials: Geographical Distribution of Enrolled Patient Population
Table 13.28 Clinical Trials: Distribution by Trial Phase
Table 13.29 Clinical Trials: Distribution by Type of Protein Degrader
Table 13.30 Clinical Trials: Distribution by Type of Protein Degrader and Trial Phase
Table 13.31 Clinical Trials: Distribution by Therapeutic Area
Table 13.32 Popular Indications: Distribution by Number of Trials
Table 13.33 Clinical Trials: Distribution by Popular Indications and Phase of Development
Table 13.34 Clinical Trials: Distribution by Study Design
Table 13.35 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 13.36 Most Active Players: Distribution by Number of Registered Trials
Table 13.37 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Table 13.38 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Table 13.39 KOLs: Distribution by Designation
Table 13.40 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Table 13.41 KOLs: Distribution by Therapeutic Area
Table 13.42 KOLs: Distribution by Type of Organization
Table 13.43 KOLs: Distribution by Location of Organization
Table 13.44 Leading Organizations: Distribution by Number of Principal Investigators
Table 13.45 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Table 13.46 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Table 13.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.48 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 13.49 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Table 13.50 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Table 13.51 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Partnership Model
Table 13.52 Leading Technology Platforms: Distribution by Number of Partnerships
Table 13.53 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.54 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Table 13.55 Most Active Players: Distribution by Number of Partnerships
Table 13.56 Most Active Players: Regional Distribution by Number of Partnerships
Table 13.57 Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Table 13.58 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Table 13.59 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Table 13.60 Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Table 13.61 Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Table 13.62 Funding and Investments: Distribution by Type of Funding
Table 13.63 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 13.64 Funding and Investments: Summary of Investments, 2014-Q3 2019 (USD Million)
Table 13.65 Popular Protein Degraders: Distribution by Number of Funding Instances
Table 13.66 Popular Protein Degraders: Distribution by Amount Invested (USD Million)
Table 13.67 Funding and Investments: Year-wise Trend of Amount Invested across Different Degraders, 2014-Q3 2019 (USD Million)
Table 13.68 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Table 13.69 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Table 13.70 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Degraders
Table 13.71 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Table 13.72 Most Active Players: Distribution by Number of Instances
Table 13.73 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 13.74 Most Active Investors: Distribution by Number of Instances
Table 13.75 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 13.76 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Conservative Scenario, 2020-2030 (USD Million)
Table 13.77 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Base Scenario, 2020-2030 (USD Million)
Table 13.78 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.79 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Conservative Scenario, 2020-2030 (USD Million)
Table 13.80 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Base Scenario, 2020-2030 (USD Million)
Table 13.81 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Optimistic Scenario, 2020-2030 (USD Million)